Celularity (CELU) Competitors $1.49 +0.01 (+0.68%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$1.52 +0.03 (+2.35%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELU vs. FATE, FDMT, PBYI, TARA, IKT, PRQR, TLSA, NKTX, CHRS, and LYELShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Fate Therapeutics (FATE), 4D Molecular Therapeutics (FDMT), Puma Biotechnology (PBYI), Protara Therapeutics (TARA), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), Tiziana Life Sciences (TLSA), Nkarta (NKTX), Coherus BioSciences (CHRS), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Celularity vs. Fate Therapeutics 4D Molecular Therapeutics Puma Biotechnology Protara Therapeutics Inhibikase Therapeutics ProQR Therapeutics Tiziana Life Sciences Nkarta Coherus BioSciences Lyell Immunopharma Fate Therapeutics (NASDAQ:FATE) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment. Which has more risk & volatility, FATE or CELU? Fate Therapeutics has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Do insiders and institutionals hold more shares of FATE or CELU? 97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 5.0% of Fate Therapeutics shares are owned by company insiders. Comparatively, 22.1% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer FATE or CELU? Fate Therapeutics received 472 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 67.51% of users gave Fate Therapeutics an outperform vote while only 42.11% of users gave Celularity an outperform vote. CompanyUnderperformOutperformFate TherapeuticsOutperform Votes48067.51% Underperform Votes23132.49% CelularityOutperform Votes842.11% Underperform Votes1157.89% Is FATE or CELU more profitable? Celularity has a net margin of -72.72% compared to Fate Therapeutics' net margin of -1,325.43%. Fate Therapeutics' return on equity of -45.88% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,325.43% -45.88% -33.95% Celularity -72.72%-119.53%-25.40% Does the media favor FATE or CELU? In the previous week, Celularity had 1 more articles in the media than Fate Therapeutics. MarketBeat recorded 4 mentions for Celularity and 3 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.80 beat Celularity's score of 0.77 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celularity 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate FATE or CELU? Fate Therapeutics currently has a consensus target price of $5.43, indicating a potential upside of 324.11%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.22Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation and earnings, FATE or CELU? Fate Therapeutics has higher earnings, but lower revenue than Celularity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M10.76-$160.93M-$1.64-0.78Celularity$48.20M0.74-$196.29MN/AN/A SummaryFate Therapeutics beats Celularity on 11 of the 16 factors compared between the two stocks. Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.24M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.5118.48Price / Sales0.74242.70395.68103.60Price / Cash0.2465.8538.1834.62Price / Book0.716.516.774.25Net Income-$196.29M$143.21M$3.22B$248.23M7 Day Performance-11.83%1.98%1.45%0.89%1 Month Performance-13.37%6.89%3.97%3.53%1 Year Performance-50.66%-2.52%16.14%5.08% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity0.3264 of 5 stars$1.49+0.7%N/A-50.8%$35.24M$48.20M0.00220FATEFate Therapeutics3.7445 of 5 stars$1.25+12.6%$5.43+334.3%-67.6%$143.26M$13.63M-0.76550Upcoming EarningsGap DownHigh Trading VolumeFDMT4D Molecular Therapeutics2.6172 of 5 stars$3.08+0.7%$26.71+767.3%-85.9%$142.61M$37,000.00-1.08120Upcoming EarningsPositive NewsPBYIPuma Biotechnology3.804 of 5 stars$2.86flat$7.00+144.8%-37.3%$141.89M$230.47M5.96200Upcoming EarningsAnalyst RevisionTARAProtara Therapeutics2.2536 of 5 stars$3.85-1.3%$20.40+429.9%+17.4%$141.55MN/A-1.3730Analyst ForecastNews CoverageIKTInhibikase Therapeutics1.5293 of 5 stars$1.89-0.5%$6.50+243.9%+53.7%$140.51M$260,000.00-0.716News CoveragePositive NewsGap DownPRQRProQR Therapeutics2.9004 of 5 stars$1.32+15.8%$9.50+619.7%-14.4%$138.88M$18.91M-4.13180Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageTLSATiziana Life Sciences0.5129 of 5 stars$1.13+5.6%N/A+110.0%$132.04MN/A0.008Short Interest ↑News CoverageNKTXNkarta2.832 of 5 stars$1.85+2.2%$14.86+703.1%-68.3%$131.27MN/A-0.98140Upcoming EarningsPositive NewsCHRSCoherus BioSciences3.532 of 5 stars$1.06-5.4%$5.38+407.1%-47.4%$129.81M$266.96M-13.25330Upcoming EarningsAnalyst ForecastNews CoverageGap DownLYELLyell Immunopharma3.3977 of 5 stars$0.44+0.9%$1.00+128.5%-78.1%$129.25M$61,000.00-0.55270Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies FATE Competitors FDMT Competitors PBYI Competitors TARA Competitors IKT Competitors PRQR Competitors TLSA Competitors NKTX Competitors CHRS Competitors LYEL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELU) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CELU Stock Free CELU Stock Alerts